Adagene Earns $2M Milestone from Exelixis in SAFEbody ADC Collaboration
Event summary
- Adagene received a $2.0 million milestone payment from Exelixis for preclinical progress on XB404, an ADC candidate using SAFEbody masking technology.
- Exelixis triggered an additional payment by selecting candidates for another SAFEbody ADC program under their collaboration.
- Adagene stands to earn development, commercialization milestones, and royalties on net sales of products developed under the agreement.
- XB404 targets ROR1/2-expressing tumors while minimizing off-tumor side effects.
- Adagene’s SAFEbody technology is designed to enhance safety and tolerability of antibody therapeutics.
The big picture
Adagene’s milestone underscores the growing industry interest in next-generation antibody-drug conjugates with improved safety profiles. The collaboration with Exelixis highlights the strategic value of SAFEbody technology in reducing off-tumor toxicity, a key challenge in ADC development. As biotech firms increasingly seek differentiated platforms, Adagene’s ability to monetize its technology through partnerships will be critical for long-term growth.
What we're watching
- Technology Validation
- Whether Adagene’s SAFEbody platform can demonstrate sustained preclinical and clinical success across multiple programs.
- Revenue Potential
- The pace at which Adagene can convert milestone payments into recurring royalties and commercialization revenue.
- Pipeline Expansion
- How Exelixis’ selection of additional SAFEbody ADC candidates may accelerate Adagene’s technology adoption in oncology.
Related topics